Prolia

Prolia
Name	Prolia

Prolia is a medication used to treat Osteoporosis in Postmenopausal women and Men with a high risk of fractures, as well as Bone metastasis in patients with solid tumors. It is developed by Amgen and has been approved by the United States Food and Drug Administration (FDA) since 2010. Prolia works by targeting the RANKL pathway, which is involved in the formation, function, and survival of osteoclasts, and has been compared to other treatments such as Denosumab and Zoledronic acid.

Introduction

Prolia is administered via Subcutaneous injection twice a year, and its effects have been studied in several clinical trials, including the FREEDOM trial and the STAND trial. The medication has been shown to reduce the risk of vertebral fractures and nonvertebral fractures in patients with Osteoporosis, and has also been used to treat patients with Giant cell tumor of bone and Bone metastasis from Prostate cancer and Breast cancer. Prolia has been compared to other treatments such as Alendronate and Ibandronate, and has been studied in combination with other medications such as Calcium and Vitamin D.

Mechanism_of_action

Prolia works by binding to RANKL, a protein that acts as a ligand for the RANK receptor, which is expressed on the surface of osteoclasts and osteoclast precursors. By inhibiting the interaction between RANKL and RANK, Prolia reduces the formation, function, and survival of osteoclasts, which are responsible for bone resorption. This mechanism of action is similar to that of other medications such as Denosumab and Opg, which also target the RANKL pathway. Prolia has been studied in patients with Multiple myeloma and Bone metastasis from Lung cancer and Renal cell carcinoma, and has been shown to reduce the risk of Skeletal-related events.

Medical_uses

Prolia is used to treat Osteoporosis in Postmenopausal women and Men with a high risk of fractures, as well as Bone metastasis in patients with solid tumors. It is also used to treat patients with Giant cell tumor of bone and Bone loss associated with Hormone replacement therapy. Prolia has been compared to other treatments such as Zoledronic acid and Pamidronate, and has been studied in combination with other medications such as Calcium and Vitamin D. The medication has been approved by regulatory agencies such as the European Medicines Agency (EMA) and the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan.

Side_effects

The most common side effects of Prolia include Hypocalcemia, Hypophosphatemia, and Skin infection. Other side effects include Musculoskeletal pain, Arthralgia, and Headache. Prolia has also been associated with an increased risk of Endocarditis and Osteonecrosis of the jaw, which are similar to the side effects seen with other medications such as Denosumab and bisphosphonates. The medication has been studied in patients with Chronic kidney disease and Liver disease, and has been shown to be safe and effective in these populations.

History

Prolia was first approved by the United States Food and Drug Administration (FDA) in 2010 for the treatment of Osteoporosis in Postmenopausal women. It was later approved for the treatment of Bone metastasis in patients with solid tumors in 2011. The medication has been developed by Amgen and has been marketed in several countries, including the United States, Europe, and Japan. Prolia has been compared to other treatments such as Zoledronic acid and Pamidronate, and has been studied in combination with other medications such as Calcium and Vitamin D.

Pharmacology

Prolia is a Monoclonal antibody that targets the RANKL pathway, which is involved in the formation, function, and survival of osteoclasts. The medication has a Half-life of approximately 28 days and is administered via Subcutaneous injection twice a year. Prolia has been studied in patients with Renal impairment and Hepatic impairment, and has been shown to be safe and effective in these populations. The medication has been compared to other treatments such as Denosumab and bisphosphonates, and has been studied in combination with other medications such as Calcium and Vitamin D. Prolia has been approved by regulatory agencies such as the European Medicines Agency (EMA) and the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan, and has been marketed by Amgen in several countries, including the United States, Europe, and Japan.

Category:Medications